Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Autor:	Emilio Iannitto, Simone Ferrero, Côme Bommier, Daniela Drandi, Martina Ferrante, Krimo Bouabdallah, Sylvain Carras, Guido Gini, Vincent Camus, Salvatrice Mancuso, Luigi Marcheselli, Angela Ferrari, Michele Merli, Benoit Tessoulin, Caterina Stelitano, Kheira Beldjord, Giovanni Roti, Fabrice Jardin, Barbara Castagnari, Francesca Palombi, Lucile Baseggio, Alexandra Traverse-Glehen, Claudio Tripodo, Anna Marina Liberati, Margherita Parolini, Sara Usai, Caterina Patti, Massimo Federico, Maurizio Musso, Marco Ladetto, Emanuele Zucca, Catherine Thieblemont
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	Diseases of the blood and blood-forming organs RC633-647.5
Zdroj:	Haematologica, Vol 999, Iss 1 (2024)
Druh dokumentu:	article
ISSN:	0390-6078 1592-8721
DOI:	10.3324/haematol.2023.284109
Popis:	Not available.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/5f4a0e9b701e495c958e1cf920f2724a Zobrazit plný text záznamu View record in DOAJ